Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway

Patent metadata

Field	Value
Publication number	US-11359013-B2
Application number	US-201916445130-A
Country	US
Kind code	B2
Filing date	Jun 18, 2019
Priority date	Jun 8, 2005
Publication date	Jun 14, 2022
Grant date	Jun 14, 2022

Abstract

The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.

First claim

The invention claimed is:

1. A method of increasing cytotoxic activity of anergic T cells in a subject having a lymphoproliferative cancer and/or decreasing a symptom of the lymphoproliferative cancer in the subject, comprising
administering to the subject having the lymphoproliferative cancer an effective amount of an agent that reduces the activity of a Programmed Cell Death (PD)-1 polypeptide, wherein the agent is an anti-PD-1 antibody,
thereby increasing the cytotoxic activity of anergic T cells and/or decreasing a symptom of the lymphoproliferative cancer in the subject, wherein the lymphoproliferative cancer is an angioimmunoblastic lymphoma.

2. The method of claim 1 , wherein increasing the cytotoxic activity of anergic T cells comprises increasing cytokine production or T cell proliferation.

3. The method of claim 2 , wherein the cytokine is interferon γ, tumor necrosis factor α or interleukin-2.

4. The method of claim 1 , further comprising measuring cytotoxic T cell activity in a biological sample from the subject.

5. The method of claim 4 , wherein measuring cytotoxic T cell activity comprises:
a) measuring the cytotoxic activity of anergic CD8+ T cells in the biological sample from the subject; or
b) measuring the production of a cytokine by T cells in the biological sample from the subject.

6. The method of claim 5 , wherein the cytokine is interferon γ, tumor necrosis factor α or interleukin-2.

7. The method of claim 1 , wherein the method further comprises administering to the subject an effective amount of a second compound that induces an immune response.

8. The compound of claim 7 , wherein the second compound is an anti-inflammatory compound, an antineoplastic compound or an analgesic.

9. The method of claim 7 , wherein the second compound is an anti-CTLA-4 antibody, an anti-BTLA antibody, or an anti-B7-H4 antibody.

10. The method of claim 7 , wherein the second compound reduces cancer cell volume.

11. The method of claim 1 , wherein the antibody is a monoclonal antibody, a humanized antibody, a deimmunized antibody, or an immunoglobulin (Ig) fusion protein.

12. The method of claim 1 , wherein the subject is human.

13. The method of claim 1 , wherein the method decreases the symptom of the lymphoproliferative cancer in the subject.

14. The method of claim 1 , wherein the method decreases the size of the tumor or the prevalence of cancer cells.

15. A method of decreasing a symptom of a lymphoproliferative cancer in a subject, comprising
administering to the subject having the lymphoproliferative cancer an effective amount of (a) an agent that reduces the activity of a Programmed Cell Death (PD)-1 polypeptide, wherein the agent is an anti-PD-1 antibody or an anti-Programmed Cell Death Ligand (PD-L1) antibody, and (b) an anti-CTLA-4 antibody,
thereby decreasing the symptom of the lymphoproliferative cancer,
wherein the lymphoproliferative cancer is a Hodgkin's lymphoma or angioimmunoblastic lymphoma.

16. The method of claim 15 , wherein the lymphoproliferative cancer is the Hodgkin's lymphoma.

17. The method of claim 15 , wherein the Hodgkin's lymphoma is a nodular lymphocyte predominant Hodgkin's lymphoma.

18. The method of claim 15 , wherein the subject is human.

19. The method of claim 15 , wherein the lymphoproliferative cancer is the angioimmunoblastic lymphoma, and wherein the method reduces the symptom of the angioimmunoblastic lymphoma.

20. The method of claim 15 , wherein
a) the anti-PD-L1 antibody is a monoclonal antibody, a humanized antibody, a deimmunized antibody, or an immunoglobulin (Ig) fusion protein; or
b) the anti-PD-1 antibody is a monoclonal antibody, a humanized antibody, a deimmunized antibody, or an Ig fusion protein.

Assignees

• Univ Emory
• Dana Farber Cancer Inst Inc
• Brigham & Womens Hospital Inc
• Harvard College

Inventors

• Freeman Gordon
• Sharpe Arlene
• Dorfman David M
• Ahmed Rafi
• Barber Daniel
• Wherry E John

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/5758

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• A61K39/395 Primary

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title

• C07K16/2818

  against CD28 or CD152 · CPC title

• A61P37/04

  Immunostimulants · CPC title